Home LiteratureArticle Details
PMID: 380427 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial

Physostigmine reversal of diazepam-induced hypnosis. A study in human volunteers.

Annals of internal medicine ·Vol. 91 ·No. 1 ·1979-07-00 ·Pages 53-5

Avant GR, Speeg KV, Freemon FR, Schenker S, Berman ML

Abstract

Under randomized double-blind conditions, 1.00 to 1.67 mg of intravenous physostigmine (Antilirium) reversed sleep induced by administration of 0.102 to 0.238 mg/kg body weight of intravenous diazepam in eight healthy human volunteers. Awakening occurred 330 to 740s after initiation of the physostigmine infusion at a rate of 0.5 mg/min every 4 min. Diazepam plasma levels were not significantly different at the start of either the physostigmine or placebo infusion. Physostigmine did not effect plasma binding of diazepam. Six subjects experienced nausea, and one subject developed an arrhythmia. Physostigmine reverses diazepam-induced hypnosis but causes side-effects requiring cautious administration.

MeSH Terms
Adult Clinical Trials as Topic Confusion/chemically induced,drug therapy Diazepam Double-Blind Method Humans Hypnosis Male Middle Aged Physostigmine/pharmacology,therapeutic use Placebos Random Allocation Sleep/drug effects Time Factors
Chemicals
Placebos Physostigmine Diazepam
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Avant G R
Speeg K V
Freemon F R
Schenker S
Berman M L
Article Info
Journal
Annals of internal medicine
Abbr.
Ann Intern Med
ISSN
0003-4819
Published
1979-07-00
Pages
53-5
Language
English
Region
United States
NLM ID
0372351
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]